Zomedica (ZOM) Investor update summary

Strategic framework and operational model

• The Five Pillars framework guides all product, partnership, and investment decisions, focusing on clinical care, client experience, workflow efficiency, cash flow, and profitability.

• Products must demonstrate measurable impact across all pillars before entering the portfolio, ensuring alignment with both clinical and financial outcomes for veterinary practices.

• The framework is designed to create recurring, sustainable revenue and deepen client relationships, supporting long-term growth.

• Integration of multiple products within a practice amplifies operational and financial benefits, increasing retention and recurring revenue.

• Sales and professional services veterinarians collaborate to drive adoption, utilization, and customer success, transforming single-product users into multi-pillar partners.

Product innovation and portfolio highlights

• TRUFORMA delivers rapid, in-clinic diagnostic results with high accuracy, expanding the range of conditions that can be managed at the point of care.

• PulseVet provides efficient, non-sedative shockwave therapy, while VETGuardian enables continuous, contactless patient monitoring.

• TRUVIEW automates cytology with AI and pathologist support, and Assisi LOOP offers home-based therapy for pain and inflammation.

• VETIGEL accelerates surgical hemostasis, reducing procedure time and improving patient safety.

• Product design emphasizes closing the gap between clinical questions and answers, enhancing both care quality and operational efficiency.

Financial performance and growth strategy

• Revenue growth is driven by consumable-based models, recurring procedure revenue, and new service lines such as monitoring fees.

• No upfront capital is required for key platforms, lowering adoption barriers and accelerating revenue capture.

• Multi-product adoption compounds margin improvement and increases switching costs, supporting durable recurring revenue.

• International sales, especially in the UK and EU, are growing rapidly, with new distributors and product launches planned.

• Management targets cash flow breakeven by Q4 2026 and GAAP profitability in 2027, with ongoing cost control and margin improvement.